Tarsus Pharmaceuticals
TARS
69 hedge funds and large institutions have $299M invested in Tarsus Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 26 increasing their positions, 18 reducing their positions, and 14 closing their positions.
28,900% more call options, than puts
Call options by funds: $870K | Put options by funds: $3K
44% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 18
39% more capital inflows, than outflows
Capital inflows: $29.5M | Capital outflows: $21.3M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.27% less ownership
Funds ownership: 76.85% → 76.58% (-0.27%)
8% less funds holding
Funds holding: 75 → 69 (-6)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RTW Investments
New York
|
+$8.69M |
| 2 |
Jefferies Financial Group
New York
|
+$7.38M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.58M |
| 4 |
BlackRock
New York
|
+$3.68M |
| 5 |
State Street
Boston,
Massachusetts
|
+$886K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cowen and Company
New York
|
-$8.94M |
| 2 |
Cormorant Asset Management
Boston,
Massachusetts
|
-$3.89M |
| 3 |
TimesSquare Capital Management
New York
|
-$1.5M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$1.49M |
| 5 |
Tang Capital Management
San Diego,
California
|
-$1.46M |
TARS Hedge Fund Activity: Q4 2022 in Review
69 of the 6,242 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q4 2022, worth a combined $299M — down 15% from $351M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of TARS and 11 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 26 added.
The largest buyer was RTW Investments, adding an estimated $8.69M. The largest seller was Cowen and Company, exiting entirely with an estimated $8.94M sold.
- 69 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q4 2022, down from 75 in Q3 2022.
- Funds reported $299M of Tarsus Pharmaceuticals stock for Q4 2022, down 15% quarter-over-quarter.
- 11 funds opened new Tarsus Pharmaceuticals positions in Q4 2022 and 14 closed out, a net change of -3 holders.
- The largest Tarsus Pharmaceuticals buyer in Q4 2022 was RTW Investments, an estimated $8.69M added.
- The largest Tarsus Pharmaceuticals seller in Q4 2022 was Cowen and Company, an estimated $8.94M sold.
Based on aggregated 13F filings for Q4 2022.